RESEARCH TRIANGLE PARK – Reactive Biosciences Inc. of Durham (formerly Boragen) has raised $4 million in debt. The company last raised more than $23 million in equity funding in the fall of 2022.
Julie Grant, the company’s CEO, signed the SEC filing for the company, which states the $4 million comes from 10 investors. The date of the first sale was June 12, according to the filing, with the filing signed ten days later.
Reactive Biosciences is focused on using the chemical boron to access previously unavailable bonding points in structure-based drug design, allowing for potentially novel medicines and solutions.
Boragen Inc. split in 2022 to facilitate boron research in three separate industries: human health, animal health, and crop protection. The crop protection arm joined forces with biotechnology company AgriMetis and formed 5Metis, also located in the Triangle.